|Articles|September 24, 2010

Elan Management Cleared Of Wrongdoing

An external review has cleared Elan Corp (Ireland) of any wrongdoing following "a number of matters" brought to the Board?s attention by some directors concerning corporate governance practices.

An external review has cleared Elan Corp (Ireland) of any wrongdoing following “a number of matters” brought to the Board’s attention by some directors concerning corporate governance practices. The review, conducted by US law firm McKenna Long & Aldridge, found “no legal breaches or other wrongdoings of any nature” by Elan management, members of its Board of Directors or its advisors. According to a company press statement, Elan’s Board of Directors has unanimously adopted the final report.

With it, the Elan Board has also accepted the report’s recommendations, including “considering the feasibility of voluntarily complying with US domestic reporting requirements notwithstanding Elan’s status as a foreign private issuer and adopting a US ‘best practices’ conflicts policy”. Elan added that the close of the investigation will bring “renewed” focus to the company.

Although the press statement provides no details about the matters investigated, a number of other sources (Reuters, The Wall Street Journal, Irish Examiner) have been discussing the background of the case. The sources claim that two Directors on the Elan Board, Vaughn Bryson and Jack Schuler, had challenged the company over transparency issues and its corporate governance, and even initiated High Court Proceedings. Many of the sources also make reference to a blog established by one of Elan’s shareholders, who is leading an investor-driven campaign to “bring accountability to the company’s Board of Directors”.

According to the Elan statement, Bryson and Schuler have “expressed their satisfaction with the outcome of the McKenna process” and have agreed to suspend the Irish High Court Proceedings. They will also resign from the Board within 90 days.

www.elan.com


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.